GENE ONLINE|News &
Opinion
Blog

2021-08-31| China

Another Homegrown Anti-PD-1 Antibody Scores Regulatory Win in China

by Tyler Chen
Share To

China had approved its fifth homegrown PD-1 targeting therapy in early August. In less than a month, the country has given another nod to a sixth.  Zimberelimab (GLS-010), which is being developed by China’s Harbin Gloria Pharmaceutical (Harbin Gloria) and Ligand Pharmaceuticals (Ligand) has bagged the regulatory win from the National Medical Products Administration (NMPA).

 

The Sixth Approved Homegrown PD-1 Therapy in China

Zimberelimab is an anti-PD-1 monoclonal antibody that is approved as the second-line treatment for patients with recurrent or refractory classical Hodgkin’s lymphoma (cHL). 

The drug is able to target PD-1, a checkpoint protein on the surface of T cells that can regulate T cells’ activation. Cancer cells will bind to PD-1 with its PD-L1 protein to hinder the immune system from activating, so tumor cells can evade the attack of T cells.

 

Clinical Progress

In the Phase 2 trial, zimberelimab delivered an overall response rate of 90.6% and a 6-month progression-free survival rate of 88.2%. Besides, the antibody received the Breakthrough Therapy Designation in March 2021 for treatment of recurrent or metastatic cervical cancer by NMPA.

Zimberelimab is out-licensed to US-based Arcus Biosciences (Arcus). Arcus is currently working with Gilead to examine the drug’s safety and efficacy profile in a Phase 1/2 clinical trial that enrolls patients with prostate, colorectal, non-small cell lung (NSCLC), pancreatic, triple-negative breast, and renal cell cancers.

 

Other Homegrown Antibodies on the List

In addition to zimberelimab, China has approved five other homegrown anti-PD-1 antibodies. The second latest approval is Akeso and Sino Biopharmaceutical’s penpulimab in August 2021. The rest are camrelizumab from Hengrui, tislelizumab from BeiGene, toripalimab from Coherus BioSciences, and sintilimab from Innovent and Eli Lilly.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Incyte’s Zynyz Secures FDA Approval for Treating a Rare and Aggressive Skin Cancer
2023-03-23
Investigate the Current Status of Rivaroxaban Generic Drug Application in China
2023-03-01
Jounce Sells Anti-CCR8 Antibody to Gilead, Forgoing $645 Million In Milestones
2022-12-28
LATEST
Novartis’ CDK4/6 Inhibitor Meets Phase 3 Endpoints In Breast Cancer
2023-03-28
BD and A*STAR collaborate to Advance Ultra-High Dimensional Analysis in Flow Cytometry for Immunology Research
2023-03-28
Vertex and CRISPR Collaborate Again with $330 Million Diabetes Gene Editing Deal
2023-03-28
Amway Applauded by Frost & Sullivan for Capitalizing on Innovative Competitive Strategies to Drive Differentiation in Its Home Water Treatment Solution in APAC
2023-03-28
BJ Bioscience Announces Clinical Collaboration with MSD to Evaluate BJ-001 in Combination with KEYTRUDA® (pembrolizumab)
2023-03-27
35% Of Better Therapeutics’ Staff to be Cut to Extend the Company’s Runway
2023-03-27
Pharming’s Joenja Racks Up FDA Approval For Rare Primary Immunodeficiency
2023-03-27
Scroll to Top